From theheart.org on Medscape

Coverage from the

Transcatheter Cardiovascular Therapeutics (TCT) 2017

October 29 - November 02, 2017; Denver, Colorado

October 29 - November 02, 2017 Denver, Colorado

TCT ORBITA: Sham Comparison Casts Doubt on PCI for Stable Angina The provocative findings, sure to be debated for years, show no difference in the exercise benefit vs a sham procedure in medically optimized, low-risk angina patients.
Medscape Medical News, November 3, 2017
TCT EXCEL: PCI, CABG Offer Similar Quality of Life at 3 Years Less invasive PCI offered early benefits, as expected, and bypass surgery was unable to surpass PCI in patient-reported left main coronary artery outcomes over 3 years.
Medscape Medical News, October 31, 2017
TCT CULPRIT-SHOCK Challenges Routine Multivessel PCI in MI, Shock But questions about the randomized trial's entry criteria and mandated PCI strategies may keep it from truly redefining the roles of multivessel vs culprit-lesion-only PCI in this high-risk population.
Medscape Medical News, October 30, 2017

Meeting Highlights At A Glance

Top News From TCT 2017: Slideshow TCT 2017 provided new insights on how to manage left main disease, more data on bioabsorbable scaffolds, and next steps in transcatheter repair.

Conference News

TCT Two Transcatheter Mitral Valves: Promising Early Experience
Medscape Medical News, November 28, 2017
TCT Trials FAVOR QFR vs FFR in Coronary Stenosis
Medscape Medical News, November 11, 2017
TCT Sapien Valve Works in 'No-Option' Secondary MV Disease
Medscape Medical News, November 10, 2017
TCT VAMPIRE 3: Tries to Breathe Life Into Distal Embolic Protection
Medscape Medical News, November 9, 2017
TCT Novel Device Shows Promise in Severe Mitral Regurgitation
Medscape Medical News, November 7, 2017
TCT FAME 2: Stable Angina With Poor Flow Benefits From PCI
Medscape Medical News, November 6, 2017
TCT Final Watchman Trial Analyses Encourage Experts, but Caveats Remain
Medscape Medical News, November 3, 2017
TCT ORBITA: Sham Comparison Casts Doubt on PCI for Stable Angina
Medscape Medical News, November 3, 2017
TCT Shorter DAPT Duration Appears Safe in ST-Elevation MI
Medscape Medical News, November 3, 2017
TCT SENIOR: DES and Shorter DAPT Better for Patients Over 75
Medscape Medical News, November 2, 2017
TCT Antibody-Enhanced DES May Shorten DAPT in ACS, Claims REDUCE
Medscape Medical News, November 2, 2017

TCT ABSORB: Bioresorbable Vascular Scaffold Fades Away in Trials
Medscape Medical News, November 2, 2017
TCT Don't Always Add CTOs to PCI for Symptomatic CAD: REVASC
Medscape Medical News, November 1, 2017
TCT Intermediate-Risk TAVR More Bang for the Buck Than Surgery
Medscape Medical News, November 1, 2017
TCT CrossBoss Catheter Fails to Trim CTO Crossing Times
Medscape Medical News, November 1, 2017
TCT DARE: Drug-Eluting Balloon Takes on DES for Stent Restenosis
Medscape Medical News, October 31, 2017
TCT Double-Kiss Crush Stenting Better for Complex LM Bifurcations
Medscape Medical News, October 31, 2017
TCT 'Hybrid' Procedure on Par With CABG, PCI in Pilot Study
Medscape Medical News, October 31, 2017
TCT EXCEL: PCI, CABG Offer Similar Quality of Life at 3 Years
Medscape Medical News, October 31, 2017
TCT CULPRIT-SHOCK Challenges Routine Multivessel PCI in MI, Shock
Medscape Medical News, October 30, 2017
TCT TCT 2017: Rich in Clinical Trials, Star Power
Medscape Medical News, October 17, 2017

Popular News from TCT 2016

EXCEL, NOBLE: Clarity, Confusion for Left Main PCI vs CABG Many say guidelines will probably change: One trial found PCI noninferior to CABG, the other gave the edge to CABG; different drug-eluting stents and endpoints were used in the trials.
Medscape Medical News, Oct 31, 2016
Watchman LAA Closure Results 'Remarkable,' Despite Cautions Postmarket registry safety and procedural success rates impressed here at TCT-16, especially as a reflection of early experience; the investigational Amulet device could become a competitor.
Medscape Medical News, Nov 3, 2016
ABSORB Trials Late Outcomes: No Clinical Gains for Bioresorbable Scaffold The everolimus-eluting bioresorbable scaffold did not fare well, clinically or in late lumen loss, against the Xience stent in the 3-year results from ABSORB II and 2-year results from ABSORB China.
Medscape Medical News, Oct 31, 2016

© WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Perspectives

Transcatheter Mitral Valve Replacement: State of the Heart
Michael J. Mack, MD; Alec S. Vahanian, MD
The Rise and Fall of BVS and the FDA Device-Approval Process
John M. Mandrola, MD; Sanjay Kaul, MD
ORBITA: Sham PCI Trial Sends Stents and CardioTwitter Reeling
Tricia Ward
DAPT Dilemmas Endure While BMS Should Fade Away
Robert A. Harrington, MD; Wayne B. Batchelor, MD, MHS; Michelle L. O'Donoghue, MD, MPH
When to Stent in Stable CAD? That Is (Still) the Question
Robert A. Harrington, MD;
David J. Maron, MD; Manesh R. Patel, MD
Revascularization in CS: Keep It Simple and Get Out of Dodge
Robert A. Harrington, MD;
Wayne B. Batchelor, MD;
Michelle L. O'Donoghue, MD, MHS
Seven Reasons New Data on Watchman Are Not Persuasive
John Mandrola, MD
Celebrities at Conferences: A Welcome Distraction?
Tricia Ward
Coronary Stents Humbled Yet Again in Stable CAD
John Mandrola, MD
Will I Feel Better? QoL Outcomes Make the Big Stage at TCT
John Mandrola, MD

Previous Coverage

Related Resource

Interventional Cardiology News & Perspectives